Claypond Capital

Claypond Capital is the family office of the Pai family, founders of the Manipal Group, and operates with $5M-$25M cheques at Series A, Series B, and growth, focused on care delivery, tech-enabled health services, and health IT software. The firm’s strategic edge is unique: portfolio companies gain meaningful access to the Manipal Hospitals network for clinical pilots, validation, and distribution, which is a non-trivial commercial unlock for B2B health software, AI clinical tools, and tech-enabled service founders. For founders, Claypond is best understood as a strategic family office that combines patient capital with the most credible domestic clinical reference customer in the Indian private hospital sector. The right founder is an Indian operator building enterprise health IT, AI-enabled clinical workflow, RCM, or tech-enabled diagnostics with revenue traction and a clear thesis on how Manipal-network adoption accelerates national rollout. Pre-revenue founders, biotech plays, and capital-intensive hospital chains seeking competition with Manipal should not approach. The cleanest entry path is via the Manipal executive network, a Claypond portfolio CEO, or sell-side bankers with India healthcare practice depth. In the pitch, lead with clinical evidence, integration roadmap with hospital information systems, multi-site deployment plans, and a credible national or international expansion narrative. Caveats: while the firm’s mandate does not list AI as a focus, AI-enabled clinical tools are very much in scope through Manipal’s adoption agenda, but partners will probe model evidence and clinical validation rigorously. Term sheets may include strategic terms tied to Manipal-network preferences, and founders should negotiate exclusivity and IP terms carefully. Decision cadence is patient family-office speed rather than venture velocity, so plan multi-month cycles and treat Claypond as a strategic anchor rather than a quick close.